Tests have shown that adipose tissue is very important in the production of chemical substances that have a major impact on atherosclerosis. The basic fat cells adiposity is very active in bio secretion hormones and other substances. Adiposities secrete chemical substances such as leptin, resistin, adiponectin, and others who participate in metabolic processes. One of the most important adipocytokine affecting the formation and the regression of atheromas plaque in the coronary blood vessels are adiponectin and resistin. So our aim was to determine the value of the concentration of adiponectin and resistin on patient with myocardial heart attack and determine their correlation with the control group of healthy subjects. In this study were included 68 subjects, 40 with myocardial heart attacks and 28 control groups of normal healthy. In the group with myocardial 78.6% of respondents were male and 21.4% female. Tests have shown that the concentration of adiponectin in the group with myocardial heart attack was significantly lower than the control group (4.94 to 6.74, p=0.043, p<0.05. In the same study group average value of resistin was significantly higher than in the control group (15.73 to 7.88, p=0.001, p<0.01) (Student's t-test, p = 0.581, p> 0.05). All this indicates that in patients with myocardial heart attack there is a decline in the concentration of adiponectin, which has cardio protective effect. The increase in resistin in myocardial heart attack in directly related to the appearance of athermanous plaques in the coronary blood vessels and has a bad prognostic significance.
Salmenniemi U, Ruotsalainen E, Pihlajamaki J, Vauhkonen I, Kainulainen S, Punnonen K. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;(25):3842–8.
2.
Goldstein B, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;(6):2563–8.
3.
Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;(6):1318–23.
4.
Schulze M, Shai I, Rimm E, Li T, Rifai N, Hu F. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;(2):534–9.
5.
Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;515–81.
6.
Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, et al. Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008;1–7.
7.
Huang C, Wu Y, Wu C, Lin L, Wu Y, Hsu P, et al. Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc Diabetol. 2013;105.
8.
Persson J, Lindberg K, Gustafsson T, Eriksson P, Paulsson-Berne G, Lundman P. Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. J Intern Med. 2010;194–205.
9.
Lee S, Park E, Kim S, E, Yoon S, Ahn Y, et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol. 2013;1029–39.
10.
Yamawaki H, Kameshima S, Usui T, Okada M, Hara Y. A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun. 2012;152–7.
11.
Okamoto Y, Ishii S, Croce K, Katsumata H, Fukushima M, Kihara S, et al. Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques. Atherosclerosis. 2013;373–7.
12.
Van De Voorde J, Pauwels B, Boydens C, Decaluwé K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;1513–21.
13.
Nakamura K, Fuster J, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;250–9.
14.
Kim J, Choi E, Mun H, Min P, Yoon Y, Lee B, et al. Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines. Cardiovasc Diabetol. 2013;140.
15.
Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004;528–33.
16.
Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, et al. Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci. 2013;455–61.
17.
Basati G, Razavi A, Abdi S, Sarrafzedegan N. Association of plasma leptin, homocysteine and nitric oxide levels with the presence and unstability of coronary artery disease. Biomark Med. 2014;405–12.
18.
Ntaios G, Gatselis N, Makaritsis K, Dalekos G. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis. 2013;216–21.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
